BriaCell Therapeutics Corp. (BCTX): Cash & Equivalents
$10.49M
As of 2025-07-31
$6.88M
As of 2026-04-30
-36.5%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-07-31 | $10.49M | n/m | 2025-10-16, Balance as of period end |
| 2024-07-31 | $862.1K | -95.9% | 2025-10-16, Balance as of period end |
| 2023-07-31 | $21.25M | -48.2% | 2024-10-29, Balance as of period end |
| 2022-07-31 | $41.04M | -28.3% | 2023-10-25, Balance as of period end |
| 2021-07-31 | $57.27M | n/a | 2022-10-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | $10.49M | n/m |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $21.03M | +290.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $2.13M | +53.1% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $8.88M | +107.5% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $19.53M | +85.1% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $681.5K | +174.4% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $20.84M | +100.6% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $8.24M | -8.5% |
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $8.67M | -13.3% |
Compare BCTX, PHIO, EMMA, MBRX side by side · Screen every company in Pharmaceutical Preparations ↗